• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

虽小却强大：作为疫苗佐剂的小分子

Tiny but mighty: small molecules as vaccine adjuvants.

作者信息

Joffe Ari, Vázquez-Maldonado Nancy, Singleton Kentner L, Leitner Wolfgang W

机构信息

Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.

Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.

出版信息

Trends Pharmacol Sci. 2024 Dec;45(12):1097-1099. doi: 10.1016/j.tips.2024.10.011. Epub 2024 Nov 8.

DOI:10.1016/j.tips.2024.10.011
PMID:39521663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11624981/
Abstract

Screening small molecule (SM) libraries now replaces traditional methods for vaccine adjuvant discovery. A study by Soni et al. highlights the use of primary human cells in high-throughput screening (HTS), leading to the discovery of a novel SM TLR7/8 agonist, PVP-037. This compound successfully restored vaccine-induced immune responses in aged mice.

摘要

筛选小分子（SM）文库如今已取代了传统的疫苗佐剂发现方法。索尼等人的一项研究强调了在高通量筛选（HTS）中使用原代人类细胞，从而发现了一种新型的小分子Toll样受体7/8（TLR7/8）激动剂PVP-037。该化合物成功恢复了衰老小鼠中疫苗诱导的免疫反应。

相似文献

1
Tiny but mighty: small molecules as vaccine adjuvants.虽小却强大：作为疫苗佐剂的小分子
Trends Pharmacol Sci. 2024 Dec;45(12):1097-1099. doi: 10.1016/j.tips.2024.10.011. Epub 2024 Nov 8.
2
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.从命中靶心到装瓶：一种咪唑并嘧啶 TLR7/8 激动剂佐剂制剂的精准发现和开发。
Sci Adv. 2024 Jul 5;10(27):eadg3747. doi: 10.1126/sciadv.adg3747. Epub 2024 Jul 3.
3
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery.用于mRNA疫苗递送的TLR7佐剂可电离脂质纳米颗粒
AAPS J. 2025 Apr 25;27(4):80. doi: 10.1208/s12248-025-01073-2.
4
Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants.新型 2,6,7-取代嘌呤衍生物的设计、合成及作为 TLR7 激动剂用于鼻腔疫苗佐剂的生物学评价。
J Med Chem. 2024 Jun 13;67(11):9389-9405. doi: 10.1021/acs.jmedchem.4c00489. Epub 2024 May 24.
5
Evaluation of the adjuvant effect of imiquimod and CpG ODN 1826 in chimeric DNA vaccine against Japanese encephalitis.评价咪喹莫特和 CpG ODN 1826 佐剂在嵌合 DNA 疫苗中的辅助作用对日本脑炎的影响。
Int Immunopharmacol. 2024 Oct 25;140:112816. doi: 10.1016/j.intimp.2024.112816. Epub 2024 Jul 30.
6
Immunostimulatory Pickering emulsion for oral vaccine delivery.用于口服疫苗递送的免疫刺激型Pickering乳液。
Int J Pharm. 2025 Aug 20;681:125890. doi: 10.1016/j.ijpharm.2025.125890. Epub 2025 Jun 23.
7
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.Toll 样受体 7/8 激动剂在疫苗佐剂中的应用。
Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208.
8
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.作为疫苗佐剂的TLR7/8激动剂的发现与递送的最新进展
Immunohorizons. 2018 Jul 2;2(6):185-197. doi: 10.4049/immunohorizons.1700063.
9
The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists.一种双佐剂新冠病毒受体结合域疫苗的合成及初步免疫学评估：Toll样受体7/8和不变自然杀伤T细胞激动剂的共价整合
Int J Biol Macromol. 2024 Jun;270(Pt 1):132258. doi: 10.1016/j.ijbiomac.2024.132258. Epub 2024 May 10.
10
Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.基于 pH 可降解纳米凝胶的强效抗病毒疫苗佐剂，该纳米凝胶通过共价键连接小分子咪唑并喹啉 TLR7/8 激动剂。
Biomaterials. 2018 Sep;178:643-651. doi: 10.1016/j.biomaterials.2018.03.026. Epub 2018 Mar 16.

本文引用的文献

1
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.从命中靶心到装瓶：一种咪唑并嘧啶 TLR7/8 激动剂佐剂制剂的精准发现和开发。
Sci Adv. 2024 Jul 5;10(27):eadg3747. doi: 10.1126/sciadv.adg3747. Epub 2024 Jul 3.
2
TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity.TLR4 配体在伤寒 Vi 多糖亚单位疫苗中有助于免疫原性。
Immunohorizons. 2024 Jan 1;8(1):29-34. doi: 10.4049/immunohorizons.2300085.
3
A protocol for high-throughput screening for immunomodulatory compounds using human primary cells.一种使用人原代细胞进行免疫调节化合物高通量筛选的方案。
STAR Protoc. 2023 Sep 15;4(3):102405. doi: 10.1016/j.xpro.2023.102405. Epub 2023 Jul 13.
4
Review: Current trends, challenges, and success stories in adjuvant research.综述：辅助研究的当前趋势、挑战和成功案例。
Front Immunol. 2023 Jan 19;14:1105655. doi: 10.3389/fimmu.2023.1105655. eCollection 2023.
5
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗（BBV152）的安全性和免疫原性：一项双盲、随机、1 期临床试验。
Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21.
6
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.TLR7/8 佐剂可克服新生儿出生时对肺炎球菌结合疫苗的低反应性。
JCI Insight. 2017 Mar 23;2(6):e91020. doi: 10.1172/jci.insight.91020.
7
Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models.免疫分析Toll样受体配体：体外人血模型中免疫刺激和促炎特征的比较。
Hum Vaccin. 2010 Apr;6(4):322-35. doi: 10.4161/hv.6.4.10866. Epub 2010 Apr 7.
8
Resiquimod and other immune response modifiers as vaccine adjuvants.瑞喹莫德及其他免疫反应调节剂作为疫苗佐剂
Expert Rev Vaccines. 2007 Oct;6(5):835-47. doi: 10.1586/14760584.6.5.835.
9
Structure-activity relationship of synthetic toll-like receptor 4 agonists.合成 Toll 样受体 4 激动剂的构效关系
J Biol Chem. 2004 Feb 6;279(6):4440-9. doi: 10.1074/jbc.M310760200. Epub 2003 Oct 21.
10
Imiquimod.咪喹莫特
Curr Opin Infect Dis. 2003 Apr;16(2):85-9. doi: 10.1097/00001432-200304000-00004.